Psoriasis: 1 in 5 patients has psoriatic arthritis, says meta-analysis

  • J Am Acad Dermatol

  • curated by Miriam Davis, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In a meta-analysis of 976,408 patients with psoriasis, the pooled prevalence of psoriatic arthritis (PsA) is 19.7% across all patients and 24.6% in moderate-to-severe disease.

Why this matters

  • Clinicians may wish to screen all patients with psoriasis, especially those with moderate-to-severe cases, for PsA.

Study design

  • Meta-analysis of 266 studies (n=976,408) that met eligibility criteria after search of PubMed, EMBASE, and Web of Science.
  • Funding: None.

Key results

  • The pooled prevalence of PsA among patients with psoriasis was 19.7% (95% CI, 18.5%-20.9%).
  • The pooled incidence ranged from 0.27 to 2.7 per 100 person-years.
  • The pooled prevalence among moderate-to-severe patients with psoriasis was 24.6% (95% CI, 22.9%-26.4%) and among children
  • PsA prevalence varied by continent:
    • Europe: 22.7% (95% CI, 20.6%-25.0%);
    • North America: 19.5% (95% CI, 17.1%-22.1%);
    • South America: 21.5% (95% CI, 15.4%-28.2%);
    • Africa: 15.5% (95% CI, 0.009%-51.5%);
    • Asia: 14.0% (95% CI, 11.7%-16.3%).
  • Using the ClASsification criteria for Psoriatic ARthritis (CASPAR), introduced in 2006, the pooled prevalence of PsA was 23.8% (95% CI, 20.1%-27.6%).

Limitations

  • Between-study heterogeneity.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit